CLIENT LOGIN
Investors2022-08-04T10:36:13-07:00
FOR INVESTORS

News, events, and reports.


Investor Presentations

Recent Healthcare Conferences

View our presentations

Scientific Evidence

MammaPrint and BluePrint Utility

View our Landmark Trials

Reach out to our investor relations department.

Contact Us

Recent Events & News

Healthcare Conferences

Agendia’s leadership team presents at healthcare conferences globally to share updates on the company and our vision for how we fit into the breast cancer treatment space

View Presentations Here

MINDACT Update

Long term follow up data for the EORTC’s landmark MINDACT trial were presented at major conferences in 2020 and confirm MammaPrint’s utility for women with breast cancer

View Data Here

NBRST Update

Five-year follow up data for Agendia’s prospective NBRST trial were presented at SABCS 2020 and confirm the utility of our tests for pre-operative treatment planning

View Data Here

SABCS 2020

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming […]

View More Information
Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Read The Article
I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View The Project

Investor News

305, 2022

Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022

May 3rd, 2022|

Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields cost-savings for breast cancer care systemically IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced that it will present new data at the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2022 taking place in Berlin, Germany on May 3-5, 2022. The first of the two poster presentations, entitled Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to Read More

2704, 2022

Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022

April 27th, 2022|

Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black women IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – April 27, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced it will present new data from ongoing clinical research evaluating its comprehensive genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place June 3-7, 2022 in Chicago, Illinois. Data will highlight Agendia’s clinical Read More

404, 2022

Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing

April 4th, 2022|

Strategic hire underscores commitment to commercial growth across genomic assay portfolio IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – April 4 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced the appointment of seasoned diagnostic and medical device executive Farida Peters-Abbadi as Vice President of Marketing, effective April 4, 2022. “Farida is an exciting addition to our executive team as we focus on accelerating commercial growth and introducing new groundbreaking products and services for breast cancer patients and their physicians,” said Betsy Hanna, Executive Vice President and Chief Commercial Officer at Agendia. “Not Read More

1503, 2022

Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy

March 15th, 2022|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced the appointment of global commercial leader Elizabeth (Betsy) Hanna as Executive Vice President and Chief Commercial Officer, effective March 15, 2022. “We are pleased to welcome Betsy as a critical member of our executive team. Betsy is a distinguished global healthcare and biotech executive with a proven track record building market value in medical device and diagnostic businesses in the US and globally,” said Mark Straley, Chief Executive Officer of Agendia. “Her extensive functional Read More

1303, 2022

GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market

March 13th, 2022|

January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients in Brazil that allows physicians to receive genomic insights from a digitized image of a tumor to predict the likelihood of metastasis in early-stage breast cancer. The rollout aligns with Agendia's long-term goal to achieve broad, global adoption for tests in its pipeline and provide results from a hematoxylin and eosin (H&E) stain that are equivalent to the information provided by its current microarray-based MammaPrint assay, the firm said. The new digital assay, called Digital MammaPrint, uses artificial intelligence technology developed thorough a collaboration between Agendia and New Read More

702, 2022

Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment

February 7th, 2022|

New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study validates genomic basis of MammaPrint High 2 category for breast cancer tumors, shows genomic testing can provide further details into biological significance and clinical behavior IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 7, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced new data published in Genes, Chromosomes and Cancer (Genes) that show MammaPrint® and BluePrint® gene signatures represent and Read More

Go to Top